{"url_path":"/sec/okur/8-k/2026-06-04/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/1637715/0001193125-26-257423-index.html","accession_number":"0001193125-26-257423","cik":"0001637715","ticker":"OKUR","issuer_name":"OnKure Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1637715/0001193125-26-257423-index.html","primary_entity_key":"0001637715","primary_entity_name":"OnKure Therapeutics, Inc."},"word_count":80,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits.\n\nExhibit No.\n\nDescription\n\n10.1\n\n \n\n[Amended and Restated 2024 Equity Incentive Plan](okur-ex10_1.htm).\n\n \n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nONKURE THERAPEUTICS, INC.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 4, 2026\n\nBy:\n\n/s/ Jason Leverone\n\n \n\n \n\n \n\nName: Jason Leverone\nTitle: Chief Financial Officer"}